65
Participants
Start Date
December 31, 2010
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Sabril
Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
Columbia University Medical Center, New York
Thomas Jefferson University, Philadelphia
CNMRI, Dover
Neuroscience & Spine Institute, Charlotte
Medical University of South Carolina, Charleston
Peachtree Neurological Clinic, Atlanta
University of South Florida, Tampa
University of Kentucky Lexington, Lexington
Aurora St. Luke's Medical Center, Milwaukee
Aurora BayCare Medical Center, Green Bay
Minnesota Epilepsy Group, PA, Saint Paul
OSF Saint Francis Medical Center, Peoria
Ochsner Clinic Foundation, New Orleans
University of Texas, Houston
University of Texas Health Science Center, San Antonio
Covenant Medical Group, Lubbock
Idaho Comprehensive Epilepsy Center, Boise
California Pacific Medical Center, San Francisco
Oregon Health and Science University, Portland
Yale Medical Center, New Haven
Sunrise Clinical Research Group, Hollywood
Dartmouth-Hitchcock Medical Center, Lebanon
Lead Sponsor
Lundbeck LLC
INDUSTRY